DPP4 and acute coronary syndrome: In addition, a meta-analysis of 70 trials of DPP-4 inhibitors enrolling 41,959 patients reported a reduction in MACE (n = 495 total events of CV death, nonfatal MI, and stroke and acute coronary syndromes and/or heart failure; odds ratio, 0.71 [95% CI, 0.59, 0.86]) [53].